Bayer’s $7.25 Billion Roundup Settlement Approved by US Judge
A Missouri judge approved Bayer AG's $7.25 billion settlement to resolve U.S. lawsuits linking Roundup weedkiller to cancer. The German company inherited the legal issues from its 2018 acquisition of Monsanto, which caused its stock to drop about 80% before recent legal wins. The case is Randall King v. Monsanto, Missouri Circuit Court Twenty-Second Judicial District (St. Louis).
How this was made
The 30-second read
Why it matters
The approval of a $7.25 billion settlement is a material financial event likely to affect Bayer's share price and risk profile.
Market read
The settlement resolves a major legal exposure for Bayer, creating a sizable cash outflow and potential stock price impact.
What to watch
The settlement may free Bayer to focus on core growth initiatives and could be offset by future earnings improvements.
Background
Bayer inherited Monsanto's Roundup litigation after its 2018 acquisition; the company has faced billions in legal costs.
Ticker impact
A Missouri judge approved Bayer AG's proposal to pay up to $7.25 billion to settle U.S. Roundup cancer lawsuits.
downward pressure as the market prices in the $7.25 billion settlement cost
The settlement amount is material and newly disclosed, representing a significant cash outflow for Bayer.
Market effects
Potential ripple effect on agro‑chemical peers as litigation risk is highlighted.
European markets may see modest pressure on other German chemical stocks.
Highlights broader regulatory and litigation exposure for multinational agribusiness firms.
Counterpoint
Some investors may view the settlement as a clean‑up that removes lingering legal uncertainty, possibly supporting a short‑term bounce.
Key entities
- CompanyBayer AG
German conglomerate and owner of Monsanto's Roundup product.
- PersonSt. Louis Circuit Judge Timothy Boyer
Judge who approved the settlement.

